Suppr超能文献

躯体共病对多发性硬化残疾进展的影响。

Effects of physical comorbidities on disability progression in multiple sclerosis.

机构信息

From the Department of Health Services, Policy and Practice (T.Z.), Brown University School of Public Health, Providence, RI; Department of Medicine (H.T., F.Z., E.K., R.C.), Division of Neurology and Centre for Brain Health, University of British Columbia, Vancouver; Department of Medicine (J.D.F., V.B., T.C.), Department of Psychiatry (J.D.F.), and School of Nursing (T.C.), Dalhousie University; Nova Scotia Health Authority (J.D.F., V.B., K.S.), Halifax; Department of Epidemiology and Biostatistics and Occupational Health (C.W.), McGill University; The Research Institute of the McGill University Health Centre (C.W.), Montreal, Quebec; Faculty of Rehabilitation Medicine (S.W.), University of Alberta, Edmonton; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

出版信息

Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.

Abstract

OBJECTIVE

To examine the association between physical comorbidities and disability progression in multiple sclerosis (MS).

METHODS

We conducted a retrospective cohort study using linked health administrative and clinical databases in 2 Canadian provinces. Participants included adults with incident MS between 1990 and 2010 who entered the cohort at their MS symptom onset date. Comorbidity status was identified with validated algorithms for health administrative data and was measured during the 1 year before study entry and throughout the study period. The outcome was the Expanded Disability Status Scale (EDSS) score as recorded at each clinic visit. We used generalized estimating equations to examine the association between physical comorbidities and EDSS scores over time, adjusting for sex, age, cohort entry year, use of disease-modifying drugs, disease course, and socioeconomic status. Meta-analyses were used to estimate overall effects across the 2 provinces.

RESULTS

We identified 3,166 individuals with incident MS. Physical comorbidity was associated with disability; with each additional comorbidity, there was a mean increase in the EDSS score of 0.18 (95% confidence interval [CI] 0.09-0.28). Among specific comorbidities, the presence of ischemic heart disease (IHD) or epilepsy was associated with higher EDSS scores (IHD 0.31, 95% CI 0.01-0.61; epilepsy 0.68, 95% CI 0.11-1.26).

CONCLUSIONS

Physical comorbidities are associated with an apparent increase in MS disability progression. Appropriate management of comorbidities needs to be determined to optimize outcomes.

摘要

目的

研究多发性硬化症(MS)患者的躯体合并症与残疾进展之间的相关性。

方法

我们开展了一项回顾性队列研究,使用加拿大 2 个省份的健康管理和临床数据库进行分析。研究对象包括 1990 年至 2010 年间发病的多发性硬化症患者,他们在多发性硬化症症状发作日期进入队列。使用健康管理数据的验证算法确定合并症状态,并在研究入组前 1 年及整个研究期间进行测量。结局是每次就诊时记录的扩展残疾状况量表(EDSS)评分。我们使用广义估计方程,调整性别、年龄、入组年份、使用疾病修正药物、疾病病程和社会经济地位后,考察躯体合并症与 EDSS 评分随时间的变化关系。使用荟萃分析估计这 2 个省份的总体影响。

结果

我们确定了 3166 名新发多发性硬化症患者。躯体合并症与残疾有关;每增加一种合并症,EDSS 评分平均增加 0.18(95%置信区间[CI]0.09-0.28)。在特定的合并症中,存在缺血性心脏病(IHD)或癫痫与更高的 EDSS 评分相关(IHD 0.31,95%CI 0.01-0.61;癫痫 0.68,95%CI 0.11-1.26)。

结论

躯体合并症与多发性硬化症残疾进展明显相关。需要确定合并症的适当管理方法,以优化治疗结局。

相似文献

1
Effects of physical comorbidities on disability progression in multiple sclerosis.
Neurology. 2018 Jan 30;90(5):e419-e427. doi: 10.1212/WNL.0000000000004885. Epub 2018 Jan 3.
2
Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
Neurology. 2018 Apr 10;90(15):e1316-e1323. doi: 10.1212/WNL.0000000000005302. Epub 2018 Mar 9.
3
Hospitalization is associated with subsequent disability in multiple sclerosis.
Mult Scler Relat Disord. 2017 May;14:23-28. doi: 10.1016/j.msard.2017.03.009. Epub 2017 Mar 24.
4
Socioeconomic status and disability progression in multiple sclerosis: A multinational study.
Neurology. 2019 Mar 26;92(13):e1497-e1506. doi: 10.1212/WNL.0000000000007190. Epub 2019 Feb 22.
5
Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes.
Mult Scler Relat Disord. 2020 Nov;46:102565. doi: 10.1016/j.msard.2020.102565. Epub 2020 Oct 5.
6
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Neurology. 2016 Apr 5;86(14):1287-1295. doi: 10.1212/WNL.0000000000002543. Epub 2016 Mar 4.
7
8
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.
Neurology. 2010 Mar 30;74(13):1041-7. doi: 10.1212/WNL.0b013e3181d6b125.
9
Premorbid Sociodemographic Status and Multiple Sclerosis Outcomes in a Universal Health Care Context.
JAMA Netw Open. 2023 Sep 5;6(9):e2334675. doi: 10.1001/jamanetworkopen.2023.34675.

引用本文的文献

1
Comorbidity and cardiovascular risk factors in multiple sclerosis.
Mult Scler J Exp Transl Clin. 2025 Jun 24;11(2):20552173251352735. doi: 10.1177/20552173251352735. eCollection 2025 Apr-Jun.
2
Comorbidity and Disease Activity in Multiple Sclerosis.
JAMA Neurol. 2024 Sep 18;81(11):1170-7. doi: 10.1001/jamaneurol.2024.2920.
3
The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics.
Ther Adv Neurol Disord. 2024 Sep 12;17:17562864241273045. doi: 10.1177/17562864241273045. eCollection 2024.
4
Assessing disease progression and treatment response in progressive multiple sclerosis.
Nat Rev Neurol. 2024 Oct;20(10):573-586. doi: 10.1038/s41582-024-01006-1. Epub 2024 Sep 9.
5
The Prevalence of Comorbidities and Their Association With Disability Progression in Individuals With Multiple Sclerosis: A Study From Brazil.
Int J MS Care. 2024 Mar 9;26(Q3):239-246. doi: 10.7224/1537-2073.2023-103. eCollection 2024 May.
6
Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
Neurology. 2024 Jul 9;103(1):e209444. doi: 10.1212/WNL.0000000000209444. Epub 2024 Jun 18.
7
Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
Neurology. 2024 Mar 26;102(6):e208051. doi: 10.1212/WNL.0000000000208051. Epub 2024 Feb 23.
8
Perceived health- related quality of life in persons with multiple sclerosis with and without a vascular comorbidity.
Qual Life Res. 2024 Feb;33(2):573-581. doi: 10.1007/s11136-023-03546-3. Epub 2023 Nov 15.
9
Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey.
Mult Scler J Exp Transl Clin. 2023 Sep 13;9(3):20552173231198588. doi: 10.1177/20552173231198588. eCollection 2023 Jul-Sep.
10
Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
Neurology. 2023 Oct 24;101(17):e1729-e1740. doi: 10.1212/WNL.0000000000207777. Epub 2023 Sep 1.

本文引用的文献

1
Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.
Mult Scler. 2017 Feb;23(2):277-285. doi: 10.1177/1352458516650512. Epub 2016 Jul 11.
2
Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review.
Neurotoxicology. 2017 Jul;61:189-212. doi: 10.1016/j.neuro.2016.03.020. Epub 2016 Apr 1.
3
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Neurology. 2016 Apr 5;86(14):1287-1295. doi: 10.1212/WNL.0000000000002543. Epub 2016 Mar 4.
4
Recommendations for observational studies of comorbidity in multiple sclerosis.
Neurology. 2016 Apr 12;86(15):1446-1453. doi: 10.1212/WNL.0000000000002474. Epub 2016 Feb 10.
5
Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study.
Mult Scler Relat Disord. 2013 Oct;2(4):355-61. doi: 10.1016/j.msard.2013.03.001. Epub 2013 Apr 2.
6
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.
Mult Scler. 2015 Mar;21(3):263-81. doi: 10.1177/1352458514564491. Epub 2015 Jan 26.
7
Comorbidity increases the risk of hospitalizations in multiple sclerosis.
Neurology. 2015 Jan 27;84(4):350-8. doi: 10.1212/WNL.0000000000001187. Epub 2014 Dec 24.
8
Vascular comorbidities in the onset and progression of multiple sclerosis.
J Neurol Sci. 2014 Dec 15;347(1-2):23-33. doi: 10.1016/j.jns.2014.10.020. Epub 2014 Oct 16.
9
An adverse lipid profile is associated with disability and progression in disability, in people with MS.
Mult Scler. 2014 Nov;20(13):1737-44. doi: 10.1177/1352458514533162. Epub 2014 May 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验